WRN Helicase: Structural Biology Services
Inhibition of the Werner syndrome RecQ helicase (WRN) is a promising approach for the treatment of cancers commonly associated with microsatellite instability.
To support drug discovery programs, we have established off-the-shelf crystallization systems to enable the determination of high-resolution X-ray crystal structures with a short turnaround time. Together with our protein production service and off-the-shelf biochemical and biophysical assays, we can provide a broad range of data to accelerate and support your drug development programs.
Structural Biology_WRN Service Platform
Related Content
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...
VIEW RESOURCEDNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCE